Biomarkers in the diagnosis and early detection of pancreatic cancer

Bibliography

• Saif MW. Translational research in pancreatic cancer. Highlights from the ‘44th ASCO Annual Meeting’. Chicago, IL, USA. May 30–June 3, 2008. JOP 2008;9(4):398-402
   PubMedGoogle Scholar
• Sarkar FH, Banerjee S, Li Y. Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 2007;224(3):326-36
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106-30
   PubMed Web of Science ®Google Scholar
• Diamantidis M, Tsapournas G, Kountouras J, Zavos C. New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr Mol Med 2008;8(1):12-37
   PubMed Web of Science ®Google Scholar
• Grote T, Logsdon CD. Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 2007;23(5):508-14
   PubMed Web of Science ®Google Scholar
• Tanase CP. Caveolin-1: a marker for pancreatic cancer diagnosis. Expert Rev Mol Diagn 2008;8(4):395-404
   PubMed Web of Science ®Google Scholar
• Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008;8:241
   PubMed Web of Science ®Google Scholar
• Goggins M. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 2007;34(4):303-10
   PubMed Web of Science ®Google Scholar
• Algul H, Schmid RM. Pancreatic cancer: a plea for good and comprehensive morphological studies. Eur J Gastroenterol Hepatol 2008;20(8):713-5
   PubMed Web of Science ®Google Scholar
• Faca VM, Song KS, Wang H, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008;5(6):e123
   PubMedGoogle Scholar
• Salek C, Benesova L, Zavoral M, et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007;13(27):3714-20
   PubMed Web of Science ®Google Scholar
• Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006;5(4):787-96
   PubMed Web of Science ®Google Scholar
• El Maalouf G, Le Tourneau C, Batty GN, et al. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 2008;35(2):167-74
   PubMed Web of Science ®Google Scholar
• Liang JJ, Kimchi ET, Staveley-O'Carroll KF, Tan D. Diagnostic and prognostic biomarkers in pancreatic carcinoma. Int J Clin Exp Pathol 2009;2(1):1-10
   PubMedGoogle Scholar
• Fujioka S, Misawa T, Okamoto T, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2007;14(6):539-44
   PubMedGoogle Scholar
• Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33(3):266-70
   PubMed Web of Science ®Google Scholar
• Misek DE, Patwa TH, Lubman DM, Simeone DM. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw 2007;5(10):1034-41
   PubMedGoogle Scholar
• Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24(18):2897-902
   PubMed Web of Science ®Google Scholar
• Grote T, Siwak DR, Fritsche HA, et al. Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 2008;8(15):3051-60
   PubMed Web of Science ®Google Scholar
• Kilic M, Gocmen E, Tez M, et al. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006;49(4):241-4
   PubMed Web of Science ®Google Scholar
• Tessler DA, Catanzaro A, Velanovich V, et al. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg 2006;191(2):191-7
   PubMed Web of Science ®Google Scholar
• Liao Q, Zhao YP, Yang YC, et al. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 2007;6(6):641-5
   PubMed Web of Science ®Google Scholar
• Sandblom G, Granroth S, Rasmussen IC. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci 2008;113(1):57-64
   PubMed Web of Science ®Google Scholar
• Gold DV, Modrak DE, Ying Z, et al. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006;24(2):252-8
   PubMed Web of Science ®Google Scholar
• Singh AP, Moniaux N, Chauhan SC, et al. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 2004;64(2):622-30
   PubMed Web of Science ®Google Scholar
• Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg 2007;14(3):243-54
   PubMedGoogle Scholar
• Jiang ZM, Xie DR, Yang Q, et al. Diagnostic performance of MUC1 for pancreatic ductal adenocarcinoma: a meta-analysis. J Clin Oncol (Meeting Abstracts) 2008;26(15S):1568
   Google Scholar
• Jeong S, Lee DH, Lee JI, et al. Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma. World J Gastroenterol 2005;11(43):6765-9
   PubMed Web of Science ®Google Scholar
• Stanton KJ, Sidner RA, Miller GA, et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 2003;186(5):486-92
   PubMed Web of Science ®Google Scholar
• Itakura J, Ishiwata T, Shen B, et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000;85(1):27-34
   PubMed Web of Science ®Google Scholar
• Tonini G, Pantano F, Vincenzi B, et al. Molecular prognostic factors in patients with pancreatic cancer. Expert Opin Ther Targets 2007;11(12):1553-69
   PubMed Web of Science ®Google Scholar
• Yan L, McFaul C, Howes N, et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005;128(7):2124-30
   PubMed Web of Science ®Google Scholar
• Buchholz M, Kestler H, Gress TM. Differential diagnosis of pancreatic tumors by molecular analysis of clinical specimens. Pancreatology 2008;8(6):551-7
   PubMed Web of Science ®Google Scholar
• Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005;4(4):523-33
   PubMed Web of Science ®Google Scholar
• Tanase CP, Raducan E, Dima SO, et al. Assessment of soluble angiogenic markers in pancreatic cancer. Biomarkers Med 2008;5:447-55
   Google Scholar
• Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition–a critical review. Anticancer Agents Med Chem 2007;7(2):223-45
   PubMed Web of Science ®Google Scholar
• Bellone G, Novarino A, Chiappino I, et al. Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy. Anticancer Res 2005;25(5):3287-91
   PubMed Web of Science ®Google Scholar
• Kobayashi A, Yamaguchi T, Ishihara T, et al. Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival. Pancreas 2005;31(1):74-8
   PubMed Web of Science ®Google Scholar
• Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88(10):2239-45
   PubMed Web of Science ®Google Scholar
• Fredriksson S, Horecka J, Brustugun OT, et al. Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem 2008;54(3):582-9
   PubMed Web of Science ®Google Scholar
• Karayiannakis AJ, Bolanaki H, Syrigos KN, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003;194(1):119-24
   PubMed Web of Science ®Google Scholar
• Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62(7):1996-2003
   PubMed Web of Science ®Google Scholar
• Kuwahara K, Sasaki T, Kuwada Y, et al. Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 2003;26(4):344-9
   PubMed Web of Science ®Google Scholar
• Chang YT, Chang MC, Wei SC, et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 2008;37(2):145-50
   PubMed Web of Science ®Google Scholar
• Lang SA, Schachtschneider P, Moser C, et al. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther 2008;7(11):3509-18
   PubMed Web of Science ®Google Scholar
• Buckhaults P, Rago C, St Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001;61(19):6996-7001
   PubMed Web of Science ®Google Scholar
• Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003;100(6):3410-5
   PubMed Web of Science ®Google Scholar
• Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004;10(7):2386-92
   PubMed Web of Science ®Google Scholar
• Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12(2):442-6
   PubMed Web of Science ®Google Scholar
• Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13(3):487-91
   PubMed Web of Science ®Google Scholar
• Bauskin AR, Brown DA, Kuffner T, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006;66(10):4983-6
   PubMed Web of Science ®Google Scholar
• Yang H, Filipovic Z, Brown D, et al. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2003;2(10):1023-9
   PubMed Web of Science ®Google Scholar
• Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;12(1):89-96
   PubMed Web of Science ®Google Scholar
• Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9(7):2642-50
   PubMed Web of Science ®Google Scholar
• Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006;4(6):766-81; quiz 665
   PubMed Web of Science ®Google Scholar
• Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol 2007;14(10):2714-20
   PubMed Web of Science ®Google Scholar
• Novotny I, Dite P, Dastych M, et al. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer. Hepatogastroenterology 2008;55(85):1475-7
   PubMed Web of Science ®Google Scholar
• Ventrucci M, Cipolla A, Racchini C, et al. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004;49(7-8):1149-55
   PubMed Web of Science ®Google Scholar
• Hardt PD, Ewald N. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Expert Rev Mol Diagn 2008;8(5):579-85
   PubMed Web of Science ®Google Scholar
• Kumar Y, Gurusamy K, Pamecha V, Davidson BR. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas 2007;35(2):114-9
   PubMed Web of Science ®Google Scholar
• Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007;34(4):436-43
   PubMed Web of Science ®Google Scholar
• Melle C, Ernst G, Escher N, et al. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem 2007;53(4):629-35
   PubMed Web of Science ®Google Scholar
• Ishizone S, Yamauchi K, Kawa S, et al. Clinical utility of quantitative RT-PCR targeted to alpha1,4-N-acetylglucosaminyltransferase mRNA for detection of pancreatic cancer. Cancer Sci 2006;97(2):119-26
   PubMed Web of Science ®Google Scholar
• Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998;4(2):271-5
   PubMed Web of Science ®Google Scholar
• Yamada T, Nakamori S, Ohzato H, et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998;4(6):1527-32
   PubMed Web of Science ®Google Scholar
• Koizumi M, Doi R, Toyoda E, et al. Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 2003;134(2):260-6
   PubMed Web of Science ®Google Scholar
• Babu DA, Deering TG, Mirmira RG. A feat of metabolic proportions: Pdx1 orchestrates islet development and function in the maintenance of glucose homeostasis. Mol Genet Metab 2007;92(1-2):43-55
   PubMed Web of Science ®Google Scholar
• Yoshida T, Shiraki N, Baba H, et al. Expression patterns of epiplakin1 in pancreas, pancreatic cancer and regenerating pancreas. Genes Cells 2008;13(7):667-78
   PubMed Web of Science ®Google Scholar
• Liu T, Gou SM, Wang CY, et al. Pancreas duodenal homeobox-1 expression and significance in pancreatic cancer. World J Gastroenterol 2007;13(18):2615-8
   PubMed Web of Science ®Google Scholar
• Quint K, Stintzing S, Alinger B, et al. The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology 2008;9(1-2):116-26
   PubMed Web of Science ®Google Scholar
• Wang XP, Li ZJ, Magnusson J, Brunicardi FC. Tissue MicroArray analyses of pancreatic duodenal homeobox-1 in human cancers. World J Surg 2005;29(3):334-8
   PubMed Web of Science ®Google Scholar
• Liu S, Ballian N, Belaguli NS, et al. PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas 2008;37(2):210-20
   PubMed Web of Science ®Google Scholar
• Nash JW, Bhardwaj A, Wen P, Frankel WL. Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study. Appl Immunohistochem Mol Morphol 2007;15(1):59-63
   PubMedGoogle Scholar
• Ohike N, Maass N, Mundhenke C, et al. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett 2003;199(2):193-200
   PubMed Web of Science ®Google Scholar
• Cao D, Zhang Q, Wu LS, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 2007;20(5):570-8
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 2008;37(2):154-8
   PubMed Web of Science ®Google Scholar
• Suzuoki M, Miyamoto M, Kato K, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002;87(10):1140-4
   PubMed Web of Science ®Google Scholar
• Tanase CP, Dima S, Mihai M, et al. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Histol 2009;40(1):23-9
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Nguyen KH, Dasgupta A, et al. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle 2008;7(19):3021-5
   PubMed Web of Science ®Google Scholar
• Mehta K, Fok J, Miller FR, et al. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004;10(23):8068-76
   PubMed Web of Science ®Google Scholar
• Verma A, Guha S, Wang H, et al. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res 2008;14(7):1997-2005
   PubMed Web of Science ®Google Scholar
• Zhao H, Mandich D, Cartun RW, Ligato S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol 2007;35(11):700-4
   PubMed Web of Science ®Google Scholar
• Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002;62(6):1868-75
   PubMed Web of Science ®Google Scholar
• Dressman D, Yan H, Traverso G, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 2003;100(15):8817-22
   PubMed Web of Science ®Google Scholar
• Shi C, Eshleman SH, Jones D, et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004;1(2):141-7
   PubMed Web of Science ®Google Scholar
• Tada M, Komatsu Y, Kawabe T, et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002;97(9):2263-70
   PubMed Web of Science ®Google Scholar
• Hoffmann AC, Mori R, Vallbohmer D, et al. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 2008;10(7):674-9
   PubMed Web of Science ®Google Scholar
• Donahue TR, Hines OJ. CXCR2 and RET Single Nucleotide Polymorphisms in Pancreatic Cancer. World J Surg 2008;33(4):710-5
   Web of Science ®Google Scholar
• Casneuf VF, Fonteyne P, Van Damme N, et al. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest 2008;26(8):852-9
   PubMed Web of Science ®Google Scholar
• Ohuchida K, Mizumoto K, Egami T, et al. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res 2006;12(18):5411-6
   PubMed Web of Science ®Google Scholar
• Jiang NY, Woda BA, Banner BF, et al. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008;17(7):1648-52
   PubMed Web of Science ®Google Scholar
• Chen J, Li D, Killary AM, et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol 2008;16(2):431-9
   PubMed Web of Science ®Google Scholar
• Reiser-erkan C, Erkan M, Pan Z, et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2008;7(9):1352-9
   PubMed Web of Science ®Google Scholar
• Karanjawala ZE, Illei PB, Ashfaq R, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 2008;32(2):188-96
   PubMed Web of Science ®Google Scholar
• Okazaki T, Jiao L, Chang P, et al. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res 2008;14(7):2042-8
   PubMed Web of Science ®Google Scholar
• Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006;66(2):1208-17
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321(5897):1801-6
   PubMed Web of Science ®Google Scholar
• Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324(5924):217
   PubMed Web of Science ®Google Scholar
• Chen R, Yi EC, Donohoe S, et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005;129(4):1187-97
   PubMed Web of Science ®Google Scholar
• Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005;129(5):1454-63
   PubMed Web of Science ®Google Scholar
• Gronborg M, Kristiansen TZ, Iwahori A, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006;5(1):157-71
   PubMed Web of Science ®Google Scholar
• Yu KH, Rustgi AK, Blair IA. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005;4(5):1742-51
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Siegel ER, Petersen GM, et al. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 2004;6(5):674-86
   PubMed Web of Science ®Google Scholar
• Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10(3):860-8
   PubMed Web of Science ®Google Scholar
• Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005;11(3):1110-8
   PubMed Web of Science ®Google Scholar
• Ehmann M, Felix K, Hartmann D, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007;34(2):205-14
   PubMed Web of Science ®Google Scholar
• Qi T, Han J, Cui Y, et al. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. J Clin Pathol 2008;61(1):49-58
   PubMed Web of Science ®Google Scholar
• Cazares LH, Diaz JI, Drake RR, Semmes OJ. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers. Methods Mol Biol 2008;428:125-40
   PubMedGoogle Scholar
• Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5(10):588-99
   PubMedGoogle Scholar
• Walch A, Rauser S, Deininger SO, Hofler H. MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology. Histochem Cell Biol 2008;130(3):421-34
   PubMed Web of Science ®Google Scholar
• Li C, Simeone DM, Brenner DE, et al. Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res 2009;8(2):483-92
   PubMed Web of Science ®Google Scholar
• Wu YM, Nowack D, Omenn G, Haab B. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 2009;8(4):1876-86
   PubMed Web of Science ®Google Scholar
• Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP 2007;8(1):4-15
   PubMedGoogle Scholar
• Pham NA, Schwock J, Iakovlev V, et al. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer 2008;8:43
   PubMedGoogle Scholar
• Liang JJ, Wang H, Rashid A, et al. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 2008;14(21):7043-9
   PubMed Web of Science ®Google Scholar
• Yip-Schneider MT, Lin A, Marshall MS. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 2001;280(4):992-7
   PubMed Web of Science ®Google Scholar
• Wang Z, Sengupta R, Banerjee S, et al. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res 2006;66(15):7653-60
   PubMed Web of Science ®Google Scholar
• Zhao S, Venkatasubbarao K, Lazor JW, et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 2008;68(11):4221-8
   PubMed Web of Science ®Google Scholar
• Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006;25(3):435-57
   PubMed Web of Science ®Google Scholar
• Lau J, Kawahira H, Hebrok M. Hedgehog signaling in pancreas development and disease. Cell Mol Life Sci 2006;63(6):642-52
   PubMed Web of Science ®Google Scholar
• Wang Z, Ma Q. Beta-catenin is a promising key factor in the SDF-1/CXCR4 axis on metastasis of pancreatic cancer. Med Hypotheses 2007;69(4):816-20
   PubMed Web of Science ®Google Scholar
• Deprimo SE, Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol 2007;18(Suppl 10):x11-19
   PubMed Web of Science ®Google Scholar
• Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32
   PubMed Web of Science ®Google Scholar
• Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005;31(4):301-16
   PubMed Web of Science ®Google Scholar